{"version":"1.0","type":"link","title":"Metabolomics and lipidomics predictor of survival in hepatocellular carcinoma patients receiving tyrosine kinase inhibitor and immune checkpoint inhibitor combination therapy.","author_name":"Guan S 외","author_url":"https://prs-insight.online/author/Guan%20S","provider_name":"PRSinsight","provider_url":"https://prs-insight.online","thumbnail_url":"https://prs-insight.online/og/paper/114149","thumbnail_width":1200,"thumbnail_height":630}